219 related articles for article (PubMed ID: 35806128)
1. The Dysregulation of MicroRNAs in the Development of Cervical Pre-Cancer-An Update.
Choi PW; Liu TL; Wong CW; Liu SK; Lum YL; Ming WK
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806128
[TBL] [Abstract][Full Text] [Related]
2. [The role of microRNAs in the pathogenesis of cervical cancer and its relationship to HPV].
Zhu YK; Cheng N; Hu Y; Cen YZ
Sheng Li Ke Xue Jin Zhan; 2012 Aug; 43(4):251-6. PubMed ID: 23189617
[TBL] [Abstract][Full Text] [Related]
3. miR-9, miR-21, miR-27b, and miR-34a Expression in HPV16/58/52-Infected Cervical Cancer.
Liu M; Wang W; Chen H; Lu Y; Yuan D; Deng Y; Ran D
Biomed Res Int; 2020; 2020():2474235. PubMed ID: 33015156
[TBL] [Abstract][Full Text] [Related]
4. The high-risk HPV oncogene E7 upregulates miR-182 expression through the TGF-β/Smad pathway in cervical cancer.
Chen J; Deng Y; Ao L; Song Y; Xu Y; Wang CC; Choy KW; Tony Chung KH; Du Q; Sui Y; Yang T; Yang J; Li H; Zou C; Tang T
Cancer Lett; 2019 Sep; 460():75-85. PubMed ID: 31247272
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-18a targeting of the STK4/MST1 tumour suppressor is necessary for transformation in HPV positive cervical cancer.
Morgan EL; Patterson MR; Ryder EL; Lee SY; Wasson CW; Harper KL; Li Y; Griffin S; Blair GE; Whitehouse A; Macdonald A
PLoS Pathog; 2020 Jun; 16(6):e1008624. PubMed ID: 32555725
[TBL] [Abstract][Full Text] [Related]
6. miR-34a negatively regulates cell cycle factor Cdt2/DTL in HPV infected cervical cancer cells.
Singh G; Sharma SK; Singh SK
BMC Cancer; 2022 Jul; 22(1):777. PubMed ID: 35840896
[TBL] [Abstract][Full Text] [Related]
7. MiR-9, miR-21, and miR-155 as potential biomarkers for HPV positive and negative cervical cancer.
Park S; Eom K; Kim J; Bang H; Wang HY; Ahn S; Kim G; Jang H; Kim S; Lee D; Park KH; Lee H
BMC Cancer; 2017 Sep; 17(1):658. PubMed ID: 28934937
[TBL] [Abstract][Full Text] [Related]
8. Regulation of cellular miRNA expression by human papillomaviruses.
Zheng ZM; Wang X
Biochim Biophys Acta; 2011; 1809(11-12):668-77. PubMed ID: 21616186
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells.
Martinez I; Gardiner AS; Board KF; Monzon FA; Edwards RP; Khan SA
Oncogene; 2008 Apr; 27(18):2575-82. PubMed ID: 17998940
[TBL] [Abstract][Full Text] [Related]
10. miRNAs signature as potential biomarkers for cervical precancerous lesions in human papillomavirus positive women.
González-Ramírez MI; Cardona YT; Agudelo MC; López C; Florez-Acosta JJ; Agudelo-Gamboa S; Garai J; Li L; Orozco-Castaño CA; Zabaleta J; Sánchez GI
Sci Rep; 2023 Jun; 13(1):9822. PubMed ID: 37330541
[TBL] [Abstract][Full Text] [Related]
11. Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells.
Hu G; Liu W; Hanania EG; Fu S; Wang T; Deisseroth AB
Cancer Gene Ther; 1995 Mar; 2(1):19-32. PubMed ID: 7621252
[TBL] [Abstract][Full Text] [Related]
12. Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29.
Li Y; Wang F; Xu J; Ye F; Shen Y; Zhou J; Lu W; Wan X; Ma D; Xie X
J Pathol; 2011 Aug; 224(4):484-95. PubMed ID: 21503900
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus 16 E6 modulates the expression of host microRNAs in cervical cancer.
Ben W; Yang Y; Yuan J; Sun J; Huang M; Zhang D; Zheng J
Taiwan J Obstet Gynecol; 2015 Aug; 54(4):364-70. PubMed ID: 26384051
[TBL] [Abstract][Full Text] [Related]
14. miR-2861 acts as a tumor suppressor via targeting EGFR/AKT2/CCND1 pathway in cervical cancer induced by human papillomavirus virus 16 E6.
Xu J; Wan X; Chen X; Fang Y; Cheng X; Xie X; Lu W
Sci Rep; 2016 Jul; 6():28968. PubMed ID: 27364926
[TBL] [Abstract][Full Text] [Related]
15. Triage of high-risk HPV-positive women in population-based screening by miRNA expression analysis in cervical scrapes; a feasibility study.
Babion I; Snoek BC; Novianti PW; Jaspers A; van Trommel N; Heideman DAM; Meijer CJLM; Snijders PJF; Steenbergen RDM; Wilting SM
Clin Epigenetics; 2018; 10():76. PubMed ID: 29930741
[TBL] [Abstract][Full Text] [Related]
16. MiR-34a Inhibits Viability and Invasion of Human Papillomavirus-Positive Cervical Cancer Cells by Targeting E2F3 and Regulating Survivin.
Geng D; Song X; Ning F; Song Q; Yin H
Int J Gynecol Cancer; 2015 May; 25(4):707-13. PubMed ID: 25675046
[TBL] [Abstract][Full Text] [Related]
17. Identification of miRNAs dysregulated in human foreskin keratinocytes (HFKs) expressing the human papillomavirus (HPV) Type 16 E6 and E7 oncoproteins.
Yablonska S; Hoskins EE; Wells SI; Khan SA
Microrna; 2013; 2(1):2-13. PubMed ID: 25070710
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-331-3p Suppresses Cervical Cancer Cell Proliferation and E6/E7 Expression by Targeting NRP2.
Fujii T; Shimada K; Asano A; Tatsumi Y; Yamaguchi N; Yamazaki M; Konishi N
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27548144
[TBL] [Abstract][Full Text] [Related]
19. The role of HPV gene expression and selected cellular MiRNAs in lung cancer development.
Hussen BM; Ahmadi G; Marzban H; Fard Azar ME; Sorayyayi S; Karampour R; Nahand JS; Hidayat HJ; Moghoofei M
Microb Pathog; 2021 Jan; 150():104692. PubMed ID: 33301856
[TBL] [Abstract][Full Text] [Related]
20. Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: correlation with presence of papillomavirus DNA.
Rosales R; López-Contreras M; Cortes RR
J Med Virol; 2001 Dec; 65(4):736-44. PubMed ID: 11745939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
